Gout – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Gout Market Outlook

Thelansis’s “Gout Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gout treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gout Overview

Gout is a prevalent cause of chronic inflammatory arthritis, characterized by the deposition of monosodium urate (MSU) monohydrate crystals within tissues. Biochemically, gout is associated with extracellular fluid urate saturation, typically manifesting as hyperuricemia, where plasma or serum urate concentrations exceed 6.8 mg/dL (approximately 400 µmol/L), the threshold of urate solubility. Clinically, gout presents with various manifestations, including acute gout flares (recurrent episodes of inflammatory arthritis), chronic gouty arthropathy, tophaceous deposits due to urate crystal accumulation, uric acid nephrolithiasis, and chronic nephropathy. The etiology of gout is multifactorial, often involving genetic predisposition, medical comorbidities, and dietary factors. In rare instances, a single genetic mutation may lead to gout, typically in conjunction with other medical complications. Regardless of the initial trigger, elevated serum uric acid levels are an expected outcome, potentially resulting in clinical gout in susceptible individuals. Dietary modifications have been shown to influence serum uric acid levels and reduce the risk of gout. Higher consumption of meat and seafood is associated with an increased incidence of gout, while increased intake of dairy products is linked to a decreased incidence in men. Additionally, adherence to the Dietary Approaches to Stop Hypertension (DASH) diet has been shown to lower serum uric acid levels and reduce the risk of gout. Gout is also associated with several comorbid health conditions, including obesity, hypertension (HTN), chronic kidney disease (CKD), diabetes mellitus (DM), hyperlipidemia (HLD), and metabolic syndrome. Nonsteroidal anti-inflammatory drugs (NSAIDs) are most effective when initiated within 48 hours of gout symptom onset, with indomethacin and naproxen being particularly potent options. Glucocorticoids are recommended for patients with contraindications to NSAIDs and colchicine and are preferred in those with renal insufficiency.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: